— Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) reported its third-quarter 2019 adjusted earnings of $6.67 per share versus $6.36 per share expected.
— Total revenues grew by 23% to $2.05 billion versus $1.99 billion expected. Eylea sales increased by 16% to $1.19 billion.
— Dupixent sales, which soared by 141% to $633 million, drove higher profitability from antibody collaboration with Sanofi.
— Looking ahead into the full year 2019, the company lowered the Sanofi collaboration revenue outlook to the range of $490 million to $510 million from the prior range of $500 million to $530 million.
— Unreimbursed R&D expense, on a reported basis, is now expected to be $2.36 billion to $2.41 billion, and SG&A expense is now predicted to be between $1.73 billion and $1.78 billion for 2019.
— The forecast for capital expenditure is tightened to the range of $390 million to $420 million from the previous range of $380 million to $420 million for the full year.
After registering a slow recovery in the first half of the week, the markets pared these gains on Thursday and Friday. The weakness witnessed in the latter half of the
Illumina, Inc. (NASDAQ: ILMN), a pioneer in genome sequencing technology, has strived to strengthen its unique position in the healthcare sector through strategic partnerships and technological innovation. Its performance so
The COVID-19 pandemic raged through the first half of this year and continues to impact the world without signs of abating. Amid this health crisis, several companies reported strong results